CN105919988A - Preparation and application thereof - Google Patents
Preparation and application thereof Download PDFInfo
- Publication number
- CN105919988A CN105919988A CN201610314186.7A CN201610314186A CN105919988A CN 105919988 A CN105919988 A CN 105919988A CN 201610314186 A CN201610314186 A CN 201610314186A CN 105919988 A CN105919988 A CN 105919988A
- Authority
- CN
- China
- Prior art keywords
- preparation
- gallic acid
- present
- cell
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Abstract
The invention relates to a preparation and an application thereof. The preparation is gallic acid or a mixture containing the gallic acid or a compound having a gallic acid activity, and the molecular formula of the preparation is shown as (OH)3C6H2COOH.H2O. The preparation disclosed by the invention is suitable for inhibiting the growth of oral carcinoma cells, so that the preparation can be further used for treating oral carcinoma and improving an effect on treating the v. the preparation disclosed by the invention provides experimental data to the research and development of new drugs for treating the oral carcinoma in the clinical field; and the preparation is applicable to the inhabitation of the growth of the oral carcinoma cells.
Description
Technical field
The present invention relates to antitumor research and development field, particularly relate to a kind of preparation and application thereof.
Background technology
Oral cancer is to occur at the general name of the malignant tumor in oral cavity, and major part belongs to squamous cell cancer, so-called glutinous
Film morphs.Oral cancer is one of incidence malignant tumor more typically.Oral cancer is common with male.In oral cancer case,
Most common with tongue movable part cancer, it is secondly carcinoma of buccal mucosa.Generally pathological changes further away from lip near oropharynx or center line, Tumor Differentiation journey
Spending the lowest, rate of lymph-node metastasis is the highest.The mucosa differential diagnosis of diseases of getting up early is only the shallow tuberosity of table or shallow ulcer, can be with slightly
Pain.Advanced lesions generally invade to lower section muscle or bone causes organ to fix and language, dysphagia.Lymph node
Transfer mostly is under the jaw of homonymy, the upper and lower neck of digastric or middle lymphonodi cervicales.Exceed the pathological changes meeting of center line at the bottom of oral cavity, the tip of the tongue or mouth
Occur that contralateral lymph is carried down shifting.Varying in size of tumor, its rate of transform is the most different.Getting up early pathological changes (T1) is 10-20%, and mid-term is sick
Becoming (T2) is 25-30%, and advanced lesions (T3, T4) is 50-70%.Metastasis below cervical region seldom occurs.
At present, the therapeutic modality of oral cancer is divided into: excision, radiation cure, chemotherapy.Oral cancer in early days is such as
Have no that cervical lymph shifts, be then used alone operation or radiotherapy all has good treatment effect.The oral cancer of middle and advanced stage, relatively
It is suitable for making surgically to merge postoperative and radiation cure.But excision, radiation cure, chemotherapy are the most each deposited
In different side reactions.
Summary of the invention
In view of current technology above shortcomings, the present invention provides a kind of preparation and application thereof, the preparation of the present invention, answers
For suppressing oral cancer growth of tumour cell, further apply treatment oral cancer, improve the therapeutic effect of oral cancer, the present invention
Research and development for clinical treatment oral cancer new drug provide experimental basis, can be applicable to suppress in the suppression that cancer cell of oral cavity grows.
The present invention adopts the following technical scheme that
A kind of preparation, described preparation is gallic acid or the mixture containing gallic acid or contains the chemical combination that gallic acid is active
Thing.
As the preferred technical solution of the present invention, described preparation is gallic acid, and structural formula is:
, molecular formula is: (OH)3C6H2COOH.H2O。
As the preferred technical solution of the present invention, described preparation is carrier pharmaceutically or diluent.
As the preferred technical solution of the present invention, described preparation be tablet, coated tablet, capsule, injection, solution, emulsion,
Ointment, emulsifiable paste, inhalant, aerosol or suppository.
The other one side of the present invention, the purposes of a kind of preparation, described preparation is gallic acid or mixing containing gallic acid
Compound or the compound containing gallic acid activity.
As the preferred technical solution of the present invention, apply in tumour medicine.
As the preferred technical solution of the present invention, it is applied to suppress oral cancer growth of tumour cell.
As the preferred technical solution of the present invention, it is applied to treat oral cancer.
A kind of preparation of the present invention and application thereof, wherein, described preparation is gallic acid or the mixing containing gallic acid
Thing or the compound containing gallic acid activity, molecular formula is: (OH)3C6H2COOH.H2O, the preparation of the present invention, it is applied to press down
Donsole chamber cancerous protuberance tumor cell growth, further applies treatment oral cancer, improves the therapeutic effect of oral cancer, and the present invention is clinical
The research and development for the treatment of oral cancer new drug provide experimental basis, can be applicable to suppress in the suppression that cancer cell of oral cavity grows.
Accompanying drawing explanation
For the technical scheme being illustrated more clearly that in the embodiment of the present invention, below by use required in embodiment
Accompanying drawing is briefly described, it should be apparent that, the accompanying drawing in describing below is only some embodiments of the present invention, for ability
From the point of view of the those of ordinary skill of territory, on the premise of not paying creative work, it is also possible to obtain the attached of other according to these accompanying drawings
Figure.
Fig. 1 is the preparation of the present invention inhibitory action schematic diagram to oral cavity intraepithelial neoplasia cells DOK.
Fig. 2 is the inhibitory action schematic diagram of the preparation oral cavity squamous cell carcinoma cell CAL-27 of the present invention.
Fig. 3 is the inhibitory action schematic diagram of the preparation oral cavity squamous cell carcinoma cell SCC-15 of the present invention.
Detailed description of the invention
Below in conjunction with the accompanying drawing in the embodiment of the present invention, the technical scheme in the embodiment of the present invention is carried out clear, complete
Describe, it is clear that described embodiment is only a part of embodiment of the present invention rather than whole embodiments wholely.Based on
Embodiment in the present invention, it is every other that those of ordinary skill in the art are obtained under not making creative work premise
Embodiment, broadly falls into the scope of protection of the invention.
The present invention provides a kind of preparation, and preparation is gallic acid or the mixture containing gallic acid or contains gallic acid
The compound of activity, say, that said preparation can be single material, it is also possible to for the mixture containing gallic acid, and
Can also is that the compound containing gallic acid activity, wherein the concrete molecular formula of gallic acid is: (OH)3C6H2COOH.H2O,
The entitled Gallic Acid of chemistry, the numbered 5995-86-8 of CAS；Outward appearance is white powder, molecular weight 188.13, knot
Structure formula is:.Wherein configuration and the storage method of gallic acid solution is: by former for gallic acid medicine
It is dissolved in DMSO, is made into 40mg/ml and stores liquid, be stored in-20 DEG C of refrigerators.
In the present invention, said preparation can be tablet, coated tablet, capsule, injection, solution, emulsion, ointment, emulsifiable paste, suction
Enter agent, aerosol or suppository.
The another side of the present invention, the purposes of a kind of preparation, the preparation during wherein said preparation is the present invention, namely Galla Chinensis
Acid or containing gallic acid activity mixture or containing gallic acid activity compound.
In the present invention, said preparation can be applied in tumour medicine, and is applied to suppress oral cancer tumor cell raw
Long, can apply to further treat oral cancer, specifically by the shadow of mtt assay detection gallic acid oral cancer cell propagation
Ringing, Cleaning Principle is that the succinate dehydrogenase in living cells mitochondrion can make exogenous MTT be reduced to water-insoluble bluish violet
Crystallization first a ceremonial jade-ladle, used in libation is also deposited in cell, and dead cell is without this function.Dimethyl sulfoxide (DMSO) can dissolve the first a ceremonial jade-ladle, used in libation in cell, uses
Microplate reader measures its absorbance value at 490nm wavelength, in the range of certain cell number, and the amount of MTT crystallization formation and cell number
It is directly proportional.Absorbance (OD value) according to recording seeks calculation suppression ratio, judges living cells quantity.
Further, with complete culture solution by storage liquid be diluted to concentration be 25 μ g/ml, 50 μ g/ml, five times of 100 μ g/ml
Sub-acid is respectively acting on oral precancerous lesion cell DOK, cancer cell of oral cavity SCC-15, cancer cell of oral cavity CAL-27.Detect respectively
The above-mentioned three strain cell of gallic acid effect 24 hours, 48 hours, the effect of cell proliferation after 72 hours, result display Galla Chinensis
Acid is respectively provided with certain inhibitory action to the propagation of above-mentioned three strain cells.
In the present invention, the present invention has expanded gallic application approach, for being applied to gallic acid suppress oral cancer
Growth of tumour cell so that it is can further apply treatment oral cancer, improves the therapeutic effect of oral cancer.The present invention is to this chemical combination
The scope of the application of thing includes the growth inhibited for cancer cell of oral cavity, and then the propagation of suppression tumor, thus delays tumor
Deteriorate.Meanwhile, in the medical constituent being also used for Galla Chinensis in the present invention suppressing cancer cell of oral cavity to grow, it is also possible to include
The carrier of pharmaceutical acceptable.Carrier can be excipient, filler, binding agent, diluent, disintegrating agent, absorption enhancer or sweet
Taste agent, but and for being only limitted to this.Pharmaceutical preparation of the present invention can be manufactured according to the preparation method of general medicine, by gallic acid
Combining with more than one carrier, this dosage form can include lozenge, powder, granule, capsule or other preparations, but not as
Limit.
In the present invention, to be illustrated, the preparation sole active agent of the present invention is gallic acid, in other words
The present invention uses single material to reach to suppress oral cancer growth of tumour cell, treats oral cancer further, improves oral cancer
Therapeutic effect, research and development that the present invention is clinical treatment oral cancer new drug provide experimental basis, can be applicable to suppress oral cancer thin
In the suppression of intracellular growth.
A specific embodiment presented below is expanded on further the present invention.
Embodiment 1
As shown in Figure 1-Figure 3, the preparation of the present invention is used to be respectively acting on oral precancerous lesion cell DOK, cancer cell of oral cavity
SCC-15, the situation of cancer cell of oral cavity CAL-27, specific as follows:
Experiment material: oral precancerous lesion cell DOK, oral squamous cell carcinoma SCC-15 and cancer cell of oral cavity CAL-27 tri-strain,
Gallic acid storing solution, MTT, hyclone, DMEM, DMEM-F12, trypsin, DMSO, 96 orifice plates, integrated enzyme reaction labelling
Instrument, micropore concussion instrument, inverted microscope.
Dental clinic SCC-15 is incubated at DMEM-F12: hyclone: the dual anti-culture medium for 89:10:1, is placed in
5%CO2, the saturated humidity incubator of 37 DEG C is cultivated.Cell ferrum wall grows, and within 2-3 days, passes on.Oral precancerous lesion cell DOK, mouth
Chamber squamous cell carcinoma CAL-27 is incubated at DMEM: hyclone: the dual anti-culture medium for 89:10:1, is placed in 5%CO2, 37 DEG C
Saturated humidity incubator is cultivated.Cell ferrum wall grows, and within 2-3 days, passes on.
Concretely comprise the following steps: the trophophase Dental clinic SCC-15 that takes the logarithm, oral precancerous lesion cell DOK and people's tongue squama
Shape cell CAL-27 tri-strain, after trypsinization, receives suspension, centrifugal (1100r, 4min), abandons supernatant, add culture medium cell
After counting, being diluted to concentration is 5 × 104Individual/ml, adds 96 orifice plates, every hole 100ul.After cultivation overnight, remove original fluid, real
Test group add Chinese medicine extract final concentration of 100ug/ml, 50ug/ml, 25ug/ml culture fluid, matched group add containing with experiment
Organize same amount of solvent (DMSO).Remove original fluid after acting on 24h, 48h, 72h respectively, add 10ul MTT reagent, 37 degree of incubators
Take out after 4h and remove supernatant, add 100ul DMSO and after concussion 15nim, exist with integrated enzyme reaction marking appliance on micropore concussion instrument
Wavelength is that 490nm surveys absorbance (OD value), and record result obtains proliferation inhibition rate, as Figure 1-3.
From Fig. 1-Fig. 3, it can be seen that gallic acid is respectively provided with certain suppression and makees the propagation of above-mentioned three strain cells
With.
The above, the only detailed description of the invention of the present invention, but protection scope of the present invention is not limited thereto, and any
Those skilled in the art in technical scope disclosed by the invention, the change that can readily occur in or replacement, all answer
Contain within protection scope of the present invention.Therefore, protection scope of the present invention should be with described scope of the claims
Accurate.
Claims (8)
1. a preparation, it is characterised in that described preparation is gallic acid or the mixture containing gallic acid or contains five times
The compound of sub-acid activity.
A kind of preparation the most according to claim 1, it is characterised in that described preparation is gallic acid, and structural formula is:, molecular formula is: (OH)3C6H2COOH.H2O。
A kind of preparation the most according to claim 1, it is characterised in that described preparation is carrier pharmaceutically or diluent.
4. according to the arbitrary described a kind of preparation of claim 1-3, it is characterised in that described preparation is tablet, coated tablet, glue
Capsule, injection, solution, emulsion, ointment, emulsifiable paste, inhalant, aerosol or suppository.
5. the purposes of a preparation, it is characterised in that described preparation is gallic acid or the mixture containing gallic acid or contains
There is the compound of gallic acid activity.
The purposes of a kind of preparation the most according to claim 5, it is characterised in that apply in tumour medicine.
The purposes of a kind of preparation the most according to claim 5, it is characterised in that be applied to suppress oral cancer tumor cell raw
Long.
The purposes of a kind of preparation the most according to claim 5, it is characterised in that be applied to treat oral cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610314186.7A CN105919988A (en) | 2016-05-13 | 2016-05-13 | Preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610314186.7A CN105919988A (en) | 2016-05-13 | 2016-05-13 | Preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105919988A true CN105919988A (en) | 2016-09-07 |
Family
ID=56835867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610314186.7A Pending CN105919988A (en) | 2016-05-13 | 2016-05-13 | Preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105919988A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559392A (en) * | 2004-03-10 | 2005-01-05 | 牛凤兰 | Applicaton of gallic acid in prepn. of medicine for antitumor |
-
2016
- 2016-05-13 CN CN201610314186.7A patent/CN105919988A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559392A (en) * | 2004-03-10 | 2005-01-05 | 牛凤兰 | Applicaton of gallic acid in prepn. of medicine for antitumor |
Non-Patent Citations (3)
| Title |
|---|
| CHAO-LIN KUO ET AL.: "Gallic acid inhibits migration and invasion of SCC-4 human oral cancer through actions of NF-κB, Ras and matrix metalloproteinase-2 and -9", 《ONCOLOGY REPORTS》 * |
| HIDEYUKI ITO ET AL.: "Polyphenols from Eriobotrya japonica and Their Cytotoxicity against Human Oral Tumor Cell Lines", 《 CHEM. PHARM. BULL.》 * |
| 汤晓飞等: "Nrf2和NF-κB在口腔癌和癌前病变细胞中的表达及意义", 《北京口腔医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway | |
| US10265289B2 (en) | Method and medicines for treating melanoma | |
| CN107778362B (en) | Polypeptide for inhibiting migration and invasion capacity of oral squamous cell carcinoma and application thereof | |
| CN101647796A (en) | Application of osthole in preparing anti-angiogenic drugs | |
| CN104557909B (en) | 3- acyloxy replaces dextrorotation deoxidation tylophorinine derivative, its preparation method and pharmaceutical composition and purposes | |
| CN109453164A (en) | A kind of antitumor combination medicine | |
| CN102198125B (en) | Purpose of phenethyl caffeate derivatives in preparation of medicines for inhibiting angiogenesis of tumors | |
| CN102048727A (en) | Application of formononetin in preparing of medicament for restricting angiogenesis | |
| CN105919988A (en) | Preparation and application thereof | |
| CN108714149A (en) | Purposes of the garden burnet active constituent in preparing anti-tumor drug | |
| KR100671762B1 (en) | Composition of herb medicine for preventing and curing cancer | |
| CN102058579B (en) | Application of dehydrocostuslactone to preparing drug for inhibiting angiogenesis | |
| Si et al. | Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells | |
| CN106265619A (en) | DFMO or DFMO and Rhizoma Zingiberis Recens extract application in the medicine of the preparation esophageal carcinoma and the prevention of hepatocarcinoma and clinical treatment | |
| CN101283994A (en) | Application of plumbagin in preparing the medicine for preventing the blood vessel from regenerating | |
| CN106138067A (en) | Bufadienolide compound application in preparation anti-gastric cancer medicament | |
| CN108175768A (en) | The application of Imatinib and lapatinib in combination medication in fulvestrant acquired resistance cytostatics | |
| CN106924225A (en) | Application of the magnolol in antineoplastic sensitizer is prepared | |
| CN109771430A (en) | Glycocholic acid application in preparation of anti-tumor drugs | |
| CN105560224A (en) | Application of salinomycin to preparation of angiogenesis inhibiting medicine | |
| CN105147700B (en) | Quetiapine fumarate is preparing the application in treating colloid tumor medicine | |
| CN112957357B (en) | Target KLF4 ubiquitination small molecule inhibitor and application thereof | |
| TWI635867B (en) | Use of herbal composition in preparation drug for inhibiting tumor cell metastasis | |
| CN107693509A (en) | SB FI 26 are preparing the application in treating breast cancer medicines | |
| CN108236622A (en) | A kind of application of substance for lowering 36 expression of ER- α in the drug for treating disease is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160907 |
|
| RJ01 | Rejection of invention patent application after publication |